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hronic heart failure (CHF) is a debil-
itating and deadly syndrome recog-
nised as a major and increasing
public health problem in developed coun-
tries as the population ages.1 Australia has
one of the highest population growths in the
over-65-years age group,2 and therefore the
number of cases of CHF is predicted to rise
further.3 However, the true burden of CHF
in Australia has only just begun to be meas-
ured, and there is a lack of data from rural
and remote populations.3,4
The Cardiac Awareness Survey and Evalu-
ation (CASE) study, conducted in 1998,
examined the level of awareness of CHF and
management practices among Australian
general practitioners.5 The study revealed
that CHF was a common presentation in
patients aged over 60 years (two in 10
patients). Furthermore, despite 10 years of
evidence to support the use of angiotensin-
converting enzyme (ACE) inhibitors, and
strong emerging evidence for the use of β-
blockers (which were previously thought to
be contraindicated6,7), the study found that
pharmacological management with ACE
inhibitors was still relatively underutilised.
At the time, best-practice management for
patients with CHF comprised (and still com-
prises) regular specialist review; diagnostic
interventions such as echocardiography;
pharmacological treatment including ACE
inhibitors and β-blockers; non-pharmaco-
logical management involving education
and self-monitoring (daily weight and
symptom recognition); and lifestyle
changes, such as exercise, moderation of
fluid and salt intake, and smoking cessa-
tion.8,9
Significant inequalities in health are evi-
dent for rural and remote Australians for
many health indicators, and mortality from
circulatory diseases has been shown to rise
with increasing remoteness.10 Australians
living in rural and remote areas also have
less access to health care services, such as
GPs, diagnostic facilities, specialist support
and pharmaceutical services, compared with
those living in metropolitan areas.10 Cur-
rently there are no national rural and remote
CHF prevalence data, although limited
attempts have been made to derive estimates
using international data.11 A recent popula-
tion-based study involving 1275 adults aged
between 60 and 86 years found evidence of
CHF in 6.3% (previously diagnosed CHF,
5.6% [95% CI, 4.4%–7.1%]; newly diag-
nosed CHF, 0.6% [95% CI, 0.3%–1.2%]).4
However, the study did not examine urban
and rural differences in CHF prevalence, nor
provide comprehensive information on
best-practice management in the primary
care setting.
The CASE study is a rich and relevant
source of Australian data on CHF manage-
ment practices in primary care but, as yet,
has not been evaluated from a rural and
remote perspective. The aim of this study
was therefore to determine whether CHF
management differed between rural and
urban primary care settings.
METHODS
Study design and sample
The study was a secondary analysis of data
obtained from the CASE study, conducted in
1998. That study involved a large, cross-
sectional, convenience sample of GPs from
all Australian states. Each GP assessed 80
consecutive patients aged 60 years or older
for the possibility of CHF. The aims, meth-
ods and initial findings have been reported
previously.5
Diagnosis of chronic heart failure
As indicated in the original CASE report,5
diagnosis of CHF (both newly and previ-
ously diagnosed) was based on modified
World Health Organization criteria.8
Geographical dispersion
Rurality was determined using the Rural,
Remote and Metropolitan Areas (RRMA)
classification.12 This is a geographical classi-
fication based on statistical local areas
(SLAs), and allocates each SLA in Australia to
a category based on population numbers and
an index of remoteness. The RRMA classifi-
cation was used to convert population esti-
mates by SLA to estimates for each of seven
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ABSTRACT
Objective:  To determine whether primary care management of chronic heart failure 
(CHF) differed between rural and urban areas in Australia.
Design:  A cross-sectional survey stratified by Rural, Remote and Metropolitan Areas 
(RRMA) classification. The primary source of data was the Cardiac Awareness Survey and 
Evaluation (CASE) study.
Setting:  Secondary analysis of data obtained from 341 Australian general practitioners 
and 23 845 adults aged 60 years or more in 1998.
Main outcome measures:  CHF determined by criteria recommended by the World 
Health Organization, diagnostic practices, use of pharmacotherapy, and CHF-related 
hospital admissions in the 12 months before the study.
Results:  There was a significantly higher prevalence of CHF among general practice 
patients in large and small rural towns (16.1%) compared with capital city and 
metropolitan areas (12.4%) (P < 0.001). Echocardiography was used less often for 
diagnosis in rural towns compared with metropolitan areas (52.0% v 67.3%, P <0.001). 
Rates of specialist referral were also significantly lower in rural towns than in 
metropolitan areas (59.1% v 69.6%, P < 0.001), as were prescribing rates of angiotensin-
converting enzyme inhibitors (51.4% v 60.1%, P < 0.001). There was no geographical 
variation in prescribing rates of β-blockers (12.6% [rural] v 11.8% [metropolitan], P = 0.32). 
Overall, few survey participants received recommended “evidence-based practice” 
diagnosis and management for CHF (metropolitan, 4.6%; rural, 3.9%; and remote areas, 
3.7%).
Conclusions:  This study found a higher prevalence of CHF, and significantly lower use 
of recommended diagnostic methods and pharmacological treatment among patients 
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RRMA categories: capital cities; other metro-
politan centres (urban centre population
> 100 000); large rural centres (population
25 000–99 000); small rural centres (popula-
tion 10 000–24 999); other rural areas (pop-
u l a t i on < 10 000) ;  remote  c ent res
(population > 5000); and other remote areas
(population < 5000). To ensure estimates for
the less populated rural and remote areas
would be made with adequate confidence,
the seven RRMA categories were collapsed
into three: capital cities and metropolitan
areas (RRMA 1–2); large and small rural
towns (RRMA 3–4); and other rural and
remote areas (RRMA, 5–7). In the event that
the patient’s postcode was missing, the post-
code of the patient’s GP was used instead.
Analysis
Data were analysed using SPSS version
12.01 (SPSS Inc, Chicago, Ill, USA). Overall
P values for multiple contingency tables
were obtained using χ2 tests to compare
demographic characteristics and manage-
ment by geographical areas. Where signifi-
cant overall differences were found, adjusted
standardised residuals were examined to
determine which RRMA category differed
from the overall average. Adjusted standard-
ised residuals in SPSS can be interpreted as z
scores. Bonferroni corrections were applied
by dividing obtained P values by the
number of statistical comparisons made.
Additional study measures included
CHF-related hospital admissions in the 12
months before the study. These data were
obtained from GPs’ patient medical records.
To allow for meaningful analysis, the
number of admissions per patient was cat-
egorised as none, 1, 2–3 or 4–14. Pharma-
cotherapy use comprised ACE inhibitor,
diuretic (loop), β-blocker, and combinations
of ACE inhibitor and β-blocker. Evidence-
based practice was defined as use of an
echocardiogram for diagnosis, combined
with ACE inhibitor and β-blocker pharma-
cotherapy.
RESULTS
Three-hundred and forty-one GPs recruited
23 845 patients for the CASE study; 1785
patients were excluded from the analysis
because of patient refusal or missing data,
resulting in a baseline population of 22 060
patients (92.5%). Of these, 2905 were diag-
nosed with CHF: 2485 of these (86%) had
been previously diagnosed, and 420 (14%)
were newly diagnosed.
Postcode, which is essential for RRMA
classification, was missing for 1165 patients
(5.3%). Thus, the current analysis included
20 895 patients, 2735 of whom had a con-
firmed diagnosis of CHF: 2335 had been
previously diagnosed, and 400 were newly
diagnosed.
Among the 2735 patients with CHF, 1950
(71.3%) resided in capital cities and metro-
politan areas, 539 (19.7%) in large and
small rural towns, and 246 (9.0%) in other
rural and remote areas.5
Prevalence of chronic heart failure
The overall prevalence of CHF among
patients aged 60 years and over across Aus-
tralia was 13.1%, comprising previously
diagnosed cases (prevalence, 11.2%) and
newly diagnosed cases (prevalence, 1.9%)
(Box 1). Patients from capital cities and
metropolitan areas experienced a signifi-
cantly lower rate of CHF (12.4%), while
those from large and small rural towns
experienced a significantly higher rate
(16.1%). Prevalence of previously diagnosed
cases was higher in rural towns (14.1%)
(Box 1). However, there was no significant
geographical variation in prevalence of
newly diagnosed cases (Box 1).
2 Number of previously diagnosed chronic heart failure (CHF) patients with CHF-related hospital admissions in the 
12 months before the CASE study, by Rural, Remote and Metropolitan Areas (RRMA) category
Number of patients (% of patients in RRMA category; 95% CI)
No. of 
admissions 
Total
(n = 2034)*
Capital cities and 
metropolitan (n = 1440)*
Large and small 
rural towns (n = 406)*
Other rural and 
remote areas (n = 188)* χ2 (df) P†
0 1324 (65%; 63%–65%) 942 (65%; 60%–68%) 265 (65%; 60%–70%) 117 (62%; 55%–69%) 4.627 (6) 0.06
1 440 (22%; 18%–23%) 318 (22%; 19%–24%) 82 (20%; 16%–24%) 40 (21%; 16%–28%)
2–3 212 (10.4%; 9%–12%) 138 (9.6%; 8%–11%) 49 (12%; 9%–16%) 25 (13%; 9%–19%)
4–14 58 (2.9%; 2%–4%) 42 (3%; 2%–4%) 10 (2.5%; 1%–4%) 6 (3%; 1%–6%)
* Data on hospital admissions were missing for 701 patients. † Overall P values for multiple contingency tables were obtained using χ2 tests. P < 0.05 indicates a significant 
overall association between the two variables examined. Bonferroni correction was applied to multiple contingency tables. 
df = degrees of freedom. CASE = Cardiac Awareness Survey and Evaluation. ◆
1 Prevalence of chronic heart failure (CHF) in the CASE population, by Rural, Remote and Metropolitan Areas (RRMA) 
category
Diagnostic category 
Number with CHF (% of total in RRMA category; 95% CI)
Total 
(n = 20 895)
Capital cities and 
metropolitan (n = 15 770) 
Large and small 
rural towns (n = 3357)
Other rural and 
remote areas (n = 1768) χ2 (df) P*
Total with CHF 2735 (13.1%; 12%–14%) 1950 (12.4%;† 12%–13%) 539 (16.1%;‡ 15%–17%) 246 (13.9%; 12%–16%) 34.297 (2) < 0.001
Previously diagnosed 2335 (11.2%; 11%–12%) 1651 (10.5%;† 10%–11%) 475 (14.1%;‡ 13%–15%) 212 (12.0%; 10%–13%) 37.252 (2) < 0.001
Newly diagnosed 400 (1.9%; 1%–2%) 299 (1.9%; 1%–2%) 67 (1.9%; 1%–2%) 34 (1.9%; 1%–3%) 0.148 (2) 0.93
* Overall P values for multiple contingency tables were obtained using χ2 tests. P < 0.05 indicates a significant overall association between the two variables examined. 
† Percentage significantly lower than the overall average for RRMA categories. ‡ Percentage significantly higher than the overall average for RRMA categories. Bonferroni 
correction was applied to multiple contingency tables. df = degrees of freedom. CASE = Cardiac Awareness Survey and Evaluation. ◆
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Hospitalisation for chronic heart failure
The number of CHF-related hospital admis-
sions in the 12 months before the study is
shown in Box 2. Sixty-five per cent of
patients previously diagnosed with CHF had
no CHF-related hospital admissions in the
previous 12 months, while the remaining
35% had a total of 1298 admissions, the
majority having been admitted between one
and three times in that year (32%). The
mean number of admissions was 0.6 per
patient (SD, 1.19; median, 0; and range, 0–
14). There was no significant association
between patient admission rates and RRMA
geographical category (P = 0.06) (Box 2).
Comorbidities
Cardiovascular and other comorbidities,
such as hypertension, asthma and diabetes,
which may contribute to CHF in these
patients, were also examined by RRMA geo-
graphical location. There was no significant
difference in the rate of comorbidities or
multiple comorbidities by RRMA category.
Diagnosis of chronic heart failure
Use of WHO criteria: Box 3 shows GP
diagnostic practices for previously diag-
nosed and newly diagnosed cases of CHF by
RRMA geographical category. Fifteen per
cent of CHF patients were diagnosed using
the recommended modified WHO criteria.8
There was no statistically significant varia-
tion in the use of the recommended diag-
nostic criteria by GPs across RRMA
geographical categories (P = 0.22).
Echocardiography: Sixty-three per cent of
previously diagnosed patients (95% CI,
61%–65%) and 30% of newly diagnosed
patients (95% CI, 25%–35%) were referred
for an echocardiogram (Box 3). Echocardio-
gram referral was significantly more com-
mon in capital cities and metropolitan areas
compared with other RRMA categories
(P < 0.001 for previously diagnosed patients,
and P = 0.04 for newly diagnosed patients).
Specialist referral: About 66% of patients
with CHF were referred by their GP to a
specialist. When specialist referral patterns
were examined by RRMA category, referral
was significantly lower in rural and remote
areas (Box 3).
Pharmacotherapy
As originally reported in the CASE study, the
overall rate of prescription of ACE inhibitors
was 58%.5 Rates of ACE inhibitor prescrib-
ing were significantly lower in rural towns
than in other RRMA categories (Box 3). The
mean dose of ACE inhibitor (for all brands)
was within the medium–low range across all
RRMA regions. There was no statistical dif-
ference in the mean dose of ACE inhibitor
prescribed according to RRMA geographical
areas. (Angiotensin II receptor blockers were
not available for general use in 1998.)
A third (33%) of patients with CHF were
not prescribed any diuretic therapy. There
was no statistically significant difference in
prescribing rates of diuretics between cities
and rural areas (P = 0.49; 95% CI, 31%–
35%). Nor was there a statistically sig-
nificant difference in prescribing rates for
β-blockers and combined ACE inhibitor/
β-blocker by RRMA category, although fre-
quency of prescribing was generally lower in
rural and remote areas.
Evidence-based CHF management
The rate of use of evidence-based manage-
ment for CHF (diagnosis by echocardio-
graphy, and prescription of an ACE inhibitor
and β-blocker) was low overall in Australia,
and consistently low across all geographical
regions (capital cities and metropolitan
areas, 4.6%; large and small rural towns,
3.9%; and rural and remote areas, 3.7%).
DISCUSSION
This secondary analysis of the CASE study
data demonstrates significant differences
between urban and rural and remote areas
3 Diagnosis of chronic heart failure (CHF) and pharmacotherapy used, by Rural, Remote and Metropolitan Areas 
(RRMA) category
Number of patients (% of patients in RRMA category; 95% CI)
P*
Total
(n = 2735) 
Capital cities and 
metropolitan (n = 1950) 
Large and small 
rural towns (n = 539)
Other rural and 
remote areas (n = 246) 
Diagnosis
WHO criteria used 400 (14.6%; 13%–15%) 299 (15.3%; 13%–17%) 67 (12.4%; 10%–15%) 34 (13.8%; 10%–18%) 0.22
Echocardiogram
In previously diagnosed† 1423 (63.4%; 61%–65%) 1069 (67.3%;§ 64%–69%) 234 (52.1%;‡ 47%–56%) 120 (58.0%;‡ 51%–64%) < 0.001
In newly diagnosed† 105 (30.0%; 25%–35%) 90 (34.5%;§ 30%–40%) 12 (20.3%; 12%–32%) 3 (10.0%;‡ 4%–26%) 0.04
Referral to specialist† 1485 (66.4%; 64%–68%) 1100 (69.6%;§ 67%–71%) 269 (59.1%;‡ 54%–63%) 116 (57.7%;‡ 51%–64%) < 0.001
Pharmacotherapy
ACEI 1601 (58.5%; 57%–60%) 1171 (60.1%;§ 58%–62%) 277 (51.4%;‡ 47%–56%) 153 (62.2%; 56%–68%) < 0.001
Diuretic (loop) 1839 (67.2%; 65%–70%) 1305 (66.9%; 65%–69%) 373 (69.2%; 65%–73%) 161 (65.4%; 59%–71%) 0.49
β-blocker 320 (11.7%; 10%–13%) 230 (11.8%; 10%–13%) 68 (12.6%; 10%–16%) 22 (8.9%; 6%–13%) 0.32
ACEI + β-blocker 168 (6.1%; 5%–7%) 123 (6.3%; 5%–7%) 32 (5.9%; 4%–8%) 13 (5.3%; 3%–9%) 0.80
Evidence-based practice
Echocardiogram +
ACEI +β-blocker
119 (4.4%; 4%–5%) 89 (4.6%; 3%–5%) 21 (3.9%; 3%–6%) 9 (3.7%; 2%–7%) 0.70
* Overall P values for multiple contingency tables were obtained using χ2 tests. P < 0.05 indicates a significant overall association between the two variables examined. 
† Denominators may vary from totals and are based on available data for echocardiogram and referral to specialist. ‡ Percentage significantly lower than the overall 
average for RRMA categories. § Percentage significantly higher than the overall average for RRMA categories. Bonferroni correction was applied to multiple contingency 
tables. ACEI = angiotensin-converting enzyme inhibitor. WHO = World Health Organization. ◆
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in both the prevalence of CHF among
patients aged 60 years and over, and the use
of appropriate diagnostic methods and
pharmacological treatments among those
with CHF.
Specifically, a higher prevalence of CHF
was found among patients in rural areas
compared with urban areas. Rates of use of
echocardiography for diagnosis and pre-
scription of ACE inhibitors were lower in
rural and remote areas compared with
urban areas. No differences in β-blocker
prescribing were detected, possibly because
at the time of the CASE study (1998) these
agents were only beginning to be intro-
duced into clinical practice in Australia for
treatment of CHF, and prescription was
restricted to specialists.13
These data illustrate that this CHF group
had multiple comorbidities, such as diabe-
tes, asthma, hypertension, angina and valvu-
lar disease, occurring with equal frequency
across all geographical regions. This finding
has important implications in rural and
remote settings, where the burden of care
for all these conditions rests predominantly
with primary care physicians and their
multidisciplinary teams.14 The fact that rural
and remote patients were hospitalised as
often as patients living in cities has particu-
lar relevance for health policy, as specialist
cardiac services are limited in rural and
remote Australia.14 Furthermore, underutili-
sation of objective diagnostic assessment
such as echocardiography may occur for the
same reason.14 This is supported by the
lower percentage of patients from rural and
remote areas referred to specialists com-
pared with patients from metropolitan areas.
This relative underutilisation of specialists
may also underpin the lower prescribing of
ACE inhibitors among rural and remote
patients.15,16
These data have several limitations. First,
they were collected some years ago, and
their relevance to current practice could be
questioned. However, the primary purpose
of this analysis was to compare prevalence of
CHF, and methods of diagnosis and pre-
scribing between rural and remote and
urban areas. Given that there have been no
subsequent analyses of CHF management
across the Australian population, these are
the best data we have currently for these
important assessments. Furthermore, there
have been no major shifts in demographics
or distribution of resources since that time
to suggest that current findings would differ.
Another limitation is that the first Austra-
lian guidelines on heart failure management
and diagnosis were not published until
200117 (ie, after the CASE primary analysis).
Nevertheless, overseas guidelines had been
published,8 and the evidence base for CHF
management had been widely disseminated
in review publications and scientific meet-
ings.6,7,18 Furthermore, the principles of evi-
dence-based diagnosis and management
remain similar in 2006.
In addition, the results of this study
depend largely on the accuracy of the defini-
tion of rural and remote versus metropolitan
patients. Although the CASE cohort was
shown to have a similar geographical distri-
bution to the general population,19 this was
a non-randomised convenience sample, and
we acknowledge that prevalence rates were
analysed in this context. Postcodes were
fundamental to the RRMA stratification.
This secondary analysis also revealed 1165
missing patient postcodes (5.3%); conse-
quently denominators for some results may
vary from the original CASE report.5
In summary, the findings of this study
suggest that there is a higher prevalence of
CHF in rural and remote areas compared
with urban areas of Australia, along with
less likelihood of diagnosis using the objec-
tive criteria of echocardiography and under-
prescribing of evidence-based therapy.
Although this study needs to be repeated
with a more contemporary patient sample,
the findings suggest that greater allocation
of resources and improved access to special-
ists and diagnostic support need to be
considered for rural and remote popula-
tions, to match those available in metropol-
itan areas.
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